ABSTRACT T
INTRODUCTION N
Severall studies have indicated that small differences in baseline concentrations of Creactivee protein in apparently healthy men and in patients with stable angina pectoris constitutee an independent risk for first cardiovascular events (129;130;193;194) . In addition,, both the increase in C-reactive protein after acute myocardial infarction and Creactivee protein concentrations during unstable angina and at discharge correlate with the riskrisk of a recurrent event. (124;128;195-198) Recently, is has been shown in patients with unstablee angina that increased C-reactive protein is associated with adverse outcome independentt of an increased cardiac troponin T or I, which are sensitive and specific markerss of myocardial necrosis and strong prognostic indicators (12;13;199) . For Creacuvee protein to be associated with outcome independently from troponin, the pathophysiologicall proces causing increases in C-reactive protein or troponin T is expectedd to be different. Increases in C-reactive protein in these patients are hypothesized too be the result of inflammatory activation, infectious or otherwise, irrespective of the presencee or absence of myocardial necrosis. Acute myocardial infarction itself induces an acute-phasee inflammatory reaction that is characterized by an increase in C-reactive protein (200) (201) (202) .. Peak C-reactive protein concentrations correlate with infarct size (196;197) ,, although this correlation is less significant after successful early reperfusionn therapy (197) . Moreover, it was demonstrated that increases in C-reactive proteinn do not occur after episodes of myocardial ischemia without necrosis in patients withh variant angina(183). Therefore, for C-reactive protein to have early prognostic significancee independent of markers of myocardial necrosis such as cardiac troponin in patientss with an acute coronary syndrome, blood samples should be taken before Creactivee protein becomes increased as a result of myocardial damage alone. The aim of thé presentt study was to characterize the early increase in C-reactive protein as a consequence off myocardial damage and compare this to the early rise in cardiac troponin T. From these data,, the optimal timing for early troponin T and C-reactive protein sampling for prognosticc purposes is proposed.
MATERIALSS AND METHODS

Consecutivee patients admitted to Cardiac Emergency Department of the Academic
Medicall Center were included in the study. Blood samples were drawn with an indwelling intravenouss catheter at 3, 4, 5, 6, 7, 8, 12, 16, 20 and 24 hours after the onset of symptoms.
Patientss were eligible for the study when there was typical chest pain suggestive of myocardiall ischemia within the previous 12 hours before admission and evidence of myocardiall damage indicated by at least one blood sample within the first 24 hours with a troponinn T > 0.1 ug/L. Exclusion criteria were severe skeletal muscle damage or trauma, cardiacc resuscitation, infectious disease or signs of inflammation, and inability or refusal to givee informed consent Patientss with ST-elevation or new left bundle branch block on the admission electrocardiogramm were treated with trombolytics, other patients were treated with aspirin, intravenouss unfraetionated heparin, intravenous nitrates and 0-blockers at the discretion of thee attending physician.
C-reactivee protein and troponin T were measured batchwise. Creatine kinase-MB isoenzymee were made available, but the physicians were unaware of C-reactive protein andd troponin T results.
Thee protocol was approved by the institutional review board, and all patients gave informedd consent.
Bloodd was collected in 10 mL heparin-coated tubes and centrifuged without delay. Cells were discarded,, and plasma was stored at -20 °C until further analysis.
Creatinee Ednase-MBm^ was measured immunochemical^ (ACS: 180 analyzer, BayerX203).
Thee upper reference limit was 7.5 u^, ^d me ^say was linear from 0 to 500 ug/L.
Troponinn T was measured by ELISA on an ES300 analyzer (Boehringer MannheimX204).
Thee upper reference limit was 0.1 jig/L, and the assay was linear from 0-15 ug/L. C-reactivé proteinn was measured with a nephelometric assay (Behring Diagnostics, Marburg, GermanyX205).. The detection limit was 0.2 mg/L, the assay was linear from 0.2-230 mg/L, andd the coefficient of variation was <3% at a concentration of 2 mg/L. For the present analysis,, we used a cutoff value of 3.0 mg/L, as reported previously (128;183;206) . All calibratorss were supplied by the manufacturers.
Patientss were divided into two groups: group 1, which included patients with a C-reactive proteinn £3.0 mg/L on admission; and group 2, which included patients with C-reactive proteinn > 3.0 mg/L on admission. The median values and interquartile range for C-reactive proteinn and troponin T were plotted for each time point. We calculated the cumulative proportionn of patients with an abnormal C-reactive protein and troponin T over the first 24 hourss after symptoms onset.
TTiee time points at which C-reactive protein and troponin T exceeded the cutoff values were recordedd for each patient. The interval between these time points was compared in group 1 andd 2 using the generalized Wilcoxon signed rank test, and median difference and interquartilee range were calculated The proportions of patients mat were treated with trombolyticss in group 1 and 2 were compared with the chi-square test. 2B).. Although the increases in C-reactive protein and troponin T were less profound in the patientss not treated with thrombolytic therapy, the patterns were similar, with an early increasee in troponin T and a time lag of several hours before C-reactive protein began to increase.. The cumulative proportion of patients with a sample above the cut-off value for Creactivee protein and troponin T over time are shown in figure 3. In the patients who received thrombolyticss (figure 3A), at 5 and 6 hours after the onset of symptoms, 68% and 84% of patientss had an abnormal troponin T, whereas only 8% and 18% of patients had an abnormal C-reactivee protein concentration (p<0.01). For patients not recieving thrombolytics ( figure   3B ),, at 5 and 6 hours, 46% and 62% had an abnormal troponin T, and 5% and 11% had an abnormall C-reactive protein (p<0.01). At I2hours, cumulative proportions of abnormal Creactivee protein and troponin T in non-ST-elevation ACS patients were 27% and 89%, respectivelyy (p<0.01). Median time above the cutoff value was 20 hours for C-reactive withh creatine kinase and creatine kinase-MB. Using a reference interval of 0-10 rag/L for Creactivee protein and frequent blood sampling, they found 7 of 10 patients had an increased Creactivee protein "which began to increase 24 hours (SD 9) after onset of symptoms and peakedd after 83 (SD 30) hours". These authors already noted that, whereas on the average Creactivee protein was correlated with infarct size and increases in CK, some patients had small infarctss and a substantial increase in C-reaetive protein.
Inn the present study, we used a sensitive C-reactive protein assay with better precision in the abnormall C-reactive protein, and 76% had an abnormal troponin T. This implies that for Creaetivee protein to have prognostic value independent of troponin T, samples should be taken ass early as possible after the onset of symptoms, whereas an increase in troponin T is detectedd most reliably from 12 hours after the onset of symptoms(29;41;44). Otherwise, increasess in C-reactive protein may be the result of myocardial necrosis, which is already representedd by an increase in troponin.
Carefull timing of C-reactive protein and troponin T sampling relative to the onset of symptomss has not been performed routinely in most studies, and this may have implications forr the interpretation of the results. Predictive power of C-reactive protein independent of troponinn T may be increased with carefully timed sampling. In the study by Haverkate et al(184)) on the prognostic value of C-reactive protein in patients with stable and unstable angina,, blood sampling was not performed relative to time of symptoms, and cardiac troponinss were not measured. Toss et al. (127) reported on the prognostic value of C-reactive proteinn in a substudy of FRISC-1. Blood samples "were collected at inclusion" and the authorss noted mat both fibrinogen and C-reactive protein concentrations were higher in patientss with increased troponin compared with patients with a troponin concentration below thee cutoff. In a multivariate analysis, increased C-reactive protein was not an independent riskrisk factor for the combined endpoint in mis study. This may have been attributable to the timingg of blood sampling, which thus included patients with increased C-reactive protein solelyy as a result of myocardial damage, as is evident from the relationship between the Creactivee protein and troponin T values. In contrast, in the study by Liuzzo et al. (124) which demonstratedd that an abnormal C-reactive protein concentration is a strong prognostic indicator,, blood samples were taken on admission, patients with unstable angina pectoris had symptomss within the last 48 hours, and all had troponin T concentrations below the cutoff. In addition,, Rebuzzi et al.(198) found a strong relationship between C-reactive protein and adversee cardiac events independent of troponin T in patients with severe unstable angina pectoris.. In this study, blood samples were taken on admission, which occurred a mean of 11 hourss after the last anginal episode. Morrow et al. (13) showed in a substudy of the TDvH 11A thatt a C-reactive protein above 15.5 mg/L was associated with 14-day mortality in combinationn with increased troponin T. In the 91 patients with an abnormal rapid bedside troponinn T test, those with an elevated C-reactive protein had a 5.1% mortality rate, whereas inn patients with a normal C-reactive protein there was no mortality. In that study, samples weree drawn on enrollment, at least 6 hours after the onset of symptoms. A recent report by Ourr data are in accordance with results from the GUSTO-IIa study that indicated that in a substantiall proportion of patients, troponin T increased 8 and 16 hours after the baseline troponintroponin T measurement(131). An early invasive treatment strategy was recently shown to be beneficiall in high-risk patients identified by an increased troponin T(212), and in the MTTI registryy there was a significantly lower long-term mortality in patients admitted to hospitals favoringg a very early (<6 hrs) invasive strategy<213). In the light of these findings, an increasedd troponin T measured early after admission may direct early treatment decisions, keepingg in mind that patients with a troponin T below the cutoff on admission may show an increasee in troponin T during subsequent hours.
Thiss study has several limitations. Blood samples were taken relative to thé time of onset of symptoms.. In patients with a non-ST-elevation acute coronary syndrome, time of onset of symptomss may be uncertain. In addition, in this relatively small patient group, we focused on plasmaa kinetics of the markers, and we cannot relate our findings to the clinical follow-up of thesee patients. Finally, a careful history of preinfarction angina was not routinely recorded on admission,, and we are not able to reliably distinguish between patients with ''unheralded" or "heralded"" myocardial infarctions.
Ourr date indicate mat for increases in C-reactive protein to be an independent prognostic indicatorr in patients with an increased troponin T, only a short time window exists after the onsett of myocardial damage Airing which baseline C-reactivé protein concentrations can be measuredd in most patients. In the majority of patients with baseline C-reaetive protein values beloww the cutoff on admission, an increase in C-reactive protein at a later time point could be causedd by an inflammatory reaction that is initiated by myocardial necrosis. Thus, for early riskrisk stratification, blood samples for C-reactive protein measurements are preferably taken as soonn as possible after the onset of symptoms, if possible within 8 hours. In contrast, increased troponinn T is most reliably measured from 12 hours after the onset of symptoms. In that way, C-reactivee protein measurements could be used in combination with troponin T measurementss as part of a clinical decision protocol for early risk stratification and subsequentt treatment (e.g. glycoprotein Hb/IIIa inhibitor treatment and early percutaneous intervention)(214),, especially in patients with a non-ST-elevation acute coronary syndrome. Bothh the X andd Y axis are log scale. Data points lying on the x axis indicate values that were below the detection limit Dashedd lines indicate the cutoff values: 3.0 mg/L for C-reactive protein and 0.1 ug/L for troponin T. C-reactive proteinn values on admission were below the cutoff more often in patients receiving trombolytic therapy than in patientss not receive trombolytic therapy. However, substantial increases in C-reactive protein did occur in some patientss with normal troponin T concentrations on admission, either with ST-elevation or without ST-elevation.
